Abstract 1888P
Background
The increasing presence of cancer patients in palliative care within emergency departments (ED) worldwide calls for improved care quality. These patients often undergo unnecessary invasive procedures due to challenges in promptly assessing their treatment needs. We developed PalliScore, a rapid assessment tool aimed at helping medical professionals quickly identify palliative care patients in the ED who are less likely to benefit from invasive procedures or ICU admission.
Methods
We retrospectively analyzed data from cancer patients in palliative care admitted to the ED of our hospital in Southeast Brazil, calculating their PalliScore upon admission. This four-step tool incorporates diagnosis of an incurable and life-threatening disease, special care situations (e.g., family or medical team disagreements, uncontrolled symptoms), the “surprise question” (Would you be surprised if this patient died within the next 12 months?), and performance status (ECOG or PPS). Each criterion is scored to reflect the PalliScore, with a threshold of ≥5 suggesting a need to consider limiting invasive interventions after thorough discussion with the patient and healthcare providers.
Results
From March 2021 to July 2023, we assessed 521 patients; 70 (13.68%) received limited intervention care while 449 received intensive care. The average PalliScore was 6.50 for the limited care group and 2.77 for the intensive care group. Statistical analysis using an unpaired t-test showed a significant difference in PalliScore between the groups (odds ratio 3.73, p < 0.0001). Notably, 16.7% of patients with a PalliScore ≥ 5 still received intensive care treatments, whereas 10% of patients with a PalliScore < 5 received limited intervention care.
Conclusions
PalliScore effectively aids ED physicians in making informed decisions regarding invasive procedures and ICU admissions, thereby potentially improving the quality of care for cancer patients in palliative settings. This tool highlights the complex nature of decision-making in palliative care, emphasizing the need for sensitive and individualized patient assessments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1863P - Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 12
1864P - Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Presenter: Didier Debieuvre
Session: Poster session 12
1865P - DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers
Presenter: Alexey Tryakin
Session: Poster session 12
1866P - Metabolic and quality of life changes with the use of dexamethasone pre-paclitaxel in patients with breast cancer
Presenter: VANESSA SCONTRE
Session: Poster session 12
1867P - Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial
Presenter: Sitthichai Chanmaniloet
Session: Poster session 12
1868P - Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction: Pac-HSR score
Presenter: Radasar Sukphinetkul
Session: Poster session 12
1869P - Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
Presenter: Anton Snegovoy
Session: Poster session 12
1870P - Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy
Presenter: Giovanna Giannecchini
Session: Poster session 12
1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection
Presenter: Athina Kostara
Session: Poster session 12
1872P - Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center
Presenter: Galip Can Uyar
Session: Poster session 12